Vetr downgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a strong-buy rating to a buy rating in a research note published on Monday, February 5th. They currently have $23.57 price objective on the stock.
Several other research analysts also recently weighed in on the stock. Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $25.00 and gave the company a buy rating in a research note on Thursday, January 11th. Credit Suisse Group reiterated an underperform rating and set a $8.00 price objective (down from $14.00) on shares of Teva Pharmaceutical Industries in a research note on Monday, November 6th. Morgan Stanley upgraded shares of Teva Pharmaceutical Industries from an underweight rating to an equal weight rating and set a $18.00 price objective on the stock in a research note on Friday, December 15th. Royal Bank of Canada set a $11.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a sell rating in a research report on Wednesday, November 29th. Finally, Cantor Fitzgerald set a $10.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a hold rating in a research report on Thursday, December 14th. Ten research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $21.26.
Teva Pharmaceutical Industries (TEVA) opened at $18.86 on Monday. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $37.94. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The company has a market cap of $18,907.76, a P/E ratio of -1.16, a P/E/G ratio of 1.37 and a beta of 0.60.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. The company had revenue of $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share. The business’s quarterly revenue was down 15.9% compared to the same quarter last year. equities research analysts expect that Teva Pharmaceutical Industries will post 2.73 EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the stock. Northern Cross LLC increased its position in Teva Pharmaceutical Industries by 14.0% during the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after acquiring an additional 2,184,172 shares during the period. Schroder Investment Management Group increased its position in Teva Pharmaceutical Industries by 22.7% during the third quarter. Schroder Investment Management Group now owns 6,194,083 shares of the company’s stock worth $106,290,000 after acquiring an additional 1,147,683 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its position in Teva Pharmaceutical Industries by 4.5% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,035,644 shares of the company’s stock worth $106,271,000 after acquiring an additional 259,891 shares during the period. State Street Corp increased its position in Teva Pharmaceutical Industries by 5.1% during the second quarter. State Street Corp now owns 4,763,692 shares of the company’s stock worth $158,254,000 after acquiring an additional 232,924 shares during the period. Finally, Macquarie Group Ltd. increased its position in Teva Pharmaceutical Industries by 350.3% during the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after acquiring an additional 3,429,448 shares during the period. 51.93% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Teva Pharmaceutical Industries (TEVA) Stock Rating Lowered by Vetr” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/teva-pharmaceutical-industries-teva-lowered-to-buy-at-vetr.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.